Skip to content
Company Analysis

Boston Scientific Corporation BSX

A comprehensive view of key metrics, scores, and financial health for Boston Scientific Corporation

Overview of Boston Scientific Corporation

BSX NYQ
Healthcare Medical Devices Large Cap
Boston Scientific Corporation (BSX), is a Large Cap company, in the Medical Devices industry, last closed at $69.13, about 57.4% overvalued vs fair value, -30.1% 1Y return, placing in the top 25% of its sector.
$69.13
0.85%
As of March 13, 2026
Previous close • Vol 90d: 40.3%
52-Week Range
Market Cap
$102.58B
Enterprise Value
$112.95B
Overall Score
Scores locked

Create a free account to see overall and pillar scores for Boston Scientific Corporation.

Top Beats

Quick Facts

Website https://www.bostonscientific.c...
HQ Marlborough, MA
Employees 59,000
Fiscal year Dec 31

Next Events

Earnings Apr 22 Estimated

Fair Value Snapshot

Bear Base Bull
$26
$29
$33
Current: $69.13 -57% vs base

Engine Room Money Flow™

Large Cap

Corporate Free Cash Flow - Where revenue goes and how value is created

Flow Steps
Revenue
$20.1B
19.9%%
Gross Profit
$13.9B
20.6%%
Operating Income
$4.0B
32.3%%
Net Income
$2.9B
55.7%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Corporate Free Cash Flow

Quality & Reliability Indicators

Cash Conversion Ratio
81.9%
Good

FCF / Net Income - measures how well earnings convert to cash

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$282.0M
11.9% of FCF

Where It Leaks

Cash Flow Health some concerns
Moderate efficiency issues detected. Review active leaks below for improvement areas.
2
Active Leaks
2/2
Improving
0
High Impact
0
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Boston Scientific Corporation's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
81
/100
Strong
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Strong
88
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 100% Coverage
Trade-Off Triangle Visualization A ternary plot showing BSX's balance between Growth (30.2%), Profitability (40.3%), and Safety (29.5%). Growth 30% Safety 29% Profitability 40%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

63th percentile vs peers
63
Key Signals
Rev Growth YoY 19.9% 71p Revenue CAGR 3Y 16.5% 63p EPS CAGR 3Y 22.0% 59p TSR 79.5% 84p EPS Growth YoY 16.3% 42p
Strengths
  • Interest Coverage Ratio in top 20% of peers (8.48, 82th percentile)
  • Superior capital returns - 3 return metrics above peer median
  • Growth above peer median with strong metric coverage (100%)
Risks

No significant risks identified for this axis.

Profitability

84th percentile vs peers
84
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

61th percentile vs peers
62
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Boston Scientific Corporation.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$29.43
- - -
-57.4% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info